doi: 10.1007/s00198-017-4108-y.
Epub 2017 Jun 6.
Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
Affiliations
- PMID: 28589418
- DOI: 10.1007/s00198-017-4108-y
Item in Clipboard
Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
Osteoporos Int.
2017 Oct.
No abstract available
Similar articles
-
Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.Osteoporos Int. 2016 May;27(5):1923-5. doi: 10.1007/s00198-015-3380-y. Epub 2015 Oct 28. Osteoporos Int. 2016. PMID: 26510845
-
Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.Arch Osteoporos. 2018 Mar 21;13(1):33. doi: 10.1007/s11657-018-0439-3. Arch Osteoporos. 2018. PMID: 29564735 Free PMC article.
-
Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.Osteoporos Int. 2019 May;30(5):1111-1115. doi: 10.1007/s00198-018-04820-8. Epub 2019 Jan 6. Osteoporos Int. 2019. PMID: 30613866
-
Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.Ann Endocrinol (Paris). 2015 Dec;76(6):650-7. doi: 10.1016/j.ando.2015.10.009. Epub 2015 Nov 27. Ann Endocrinol (Paris). 2015. PMID: 26639186 Review.
-
Effects and management of denosumab discontinuation.Joint Bone Spine. 2018 Oct;85(5):515-517. doi: 10.1016/j.jbspin.2017.12.013. Epub 2018 Jan 6. Joint Bone Spine. 2018. PMID: 29317292 Review. No abstract available.
Cited by
-
Denosumab Discontinuation.Curr Osteoporos Rep. 2023 Feb;21(1):95-103. doi: 10.1007/s11914-022-00771-6. Epub 2022 Dec 24. Curr Osteoporos Rep. 2023. PMID: 36564572 Review.
-
The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension.J Bone Miner Res. 2023 Jan;38(1):26-34. doi: 10.1002/jbmr.4737. Epub 2022 Nov 23. J Bone Miner Res. 2023. PMID: 36333954 Free PMC article. Clinical Trial.
-
Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature.Endocrinol Metab (Seoul). 2022 Apr;37(2):183-194. doi: 10.3803/EnM.2021.1369. Epub 2022 Apr 14. Endocrinol Metab (Seoul). 2022. PMID: 35417954 Free PMC article. Review.
-
Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab.J Bone Metab. 2021 Nov;28(4):339-341. doi: 10.11005/jbm.2021.28.4.339. Epub 2021 Nov 30. J Bone Metab. 2021. PMID: 34905681 Free PMC article. No abstract available.
-
A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial.Front Med (Lausanne). 2021 Sep 8;8:717168. doi: 10.3389/fmed.2021.717168. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34568375 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
